Why is the CSL share price losing ground on Friday?

Why are CSL shares missing out on the market's gains on Friday?

| More on:
A sad looking scientist sitting and upset about a share price fall.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's shaping up to be a rather pleasant end to the week for ASX shares and the S&P/ASX 200 Index (ASX: XJO). So far this Friday, the ASX 200 has put on a healthy 0.82% and is back over 7,150 points. But the same can't be said for the CSL Limited (ASX: CSL) share price.

CSL shares, at the time of writing, are in the red today. They've lost 0.47% of their value so far and are currently going for $268.75 each. So what's going on here? After all, this is an underperformance of the broader market of more than 1%.

Why is the CSL share price dropping today?

Well, it's not entirely clear. There hasn't been any news or announcements out of CSL today. Or indeed for a few weeks now.

But what we do know is that the S&P/ASX 200 Health Care Index (ASX: XHJ) is one of the worst-performing sectors on the ASX 200 today so far. Amongst ASX healthcare shares, Virtus Health Ltd (ASX: VRT) is leading the losses.

Virtus shares are presently down by a notable 1.1%. This could be related to the news we heard this morning, that Virtus has terminated the transaction implementation deed with European company CapVest in favour of a rival offer from BGH Capital.

The Virtus board is now unanimously recommending shareholders go with the BGH offer, even though the termination with CapVest will see Virtus pay a $7.19 million break fee.

This could be what is dragging the Virtus share price down today, and by extension, Virtus' woes could be why the entire healthcare sector, including the CSL share price, is under the pump.

At the current CSL share price, this ASX 200 healthcare giant has a market capitalisation of $129.42 billion, with a dividend yield of 0.96%.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Is Medibank stock a buy for its 5.5% dividend yield?

This business is providing investors with very healthy dividends.

Read more »

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

This ASX 200 stock is charging higher on FDA approval news

This stock is avoiding the market weakness on Monday. Let's find out why.

Read more »